Sumitomo Pharma (4506) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
2 Nov, 2026Executive summary
H1 FY2027 revenue rose 17.3% YoY to ¥266.5bn; core operating profit fell 56.2% to ¥42.1bn and net profit fell 61.3% to ¥38.2bn.
U.S. ORGOVYX and GEMTESA growth drove revenue gains; higher commercial and R&D spending, mix effects and the absence of prior-year gains weighed on profit.
FY2027 revenue guidance rose to ¥565bn, with core operating profit of ¥105bn; a ¥15/share year-end dividend is planned.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sumitomo Pharma
- Revenue up 19.9% and net profit up 51.7% YoY, led by U.S. sales and FX gains.4506
Q1 2027 - FY2025 saw record profit and U.S. growth; FY2026 targets revenue gains but lower profit.4506Q4 2026
- Accelerating growth with strong product sales, pipeline innovation, and disciplined financial management.4506Investor presentation
- Core operating profit surged 408.5% on strong North America growth and Asian business gains.4506Q3 2026
- Profit and revenue rebounded on strong North America sales and China-Asia business transfer gains.4506Q2 2026
- Revenue up 19.1% year-over-year, led by ORGOVYX and GEMTESA; net profit down on FX losses.4506Q1 2026
- Revenue up 18.4%, losses narrowed, and liquidity improved on asset sales and restructuring.4506Q2 2025
- Profit rebounded on U.S. sales and cost cuts; FY2025 profit to rise despite lower revenue.4506Q4 2025
- Profitability restored and outlook raised on strong U.S. sales and cost controls.4506Q3 2025